Literature DB >> 9808604

Ovarian ablation alone promotes aortic intimal hyperplasia and accumulation of fibroblast growth factor.

C H Selzman1, J S Gaynor, A S Turner, S M Johnson, L D Horwitz, T A Whitehill, A H Harken.   

Abstract

BACKGROUND: Estrogen-mediated cardiovascular protection is incompletely explained by its beneficial lipid-modifying effects. Previous studies interrogating direct vascular effects of estrogens have used models of either diet- or injury-induced atherosclerosis. The purpose of this study was to determine the influence of ovarian ablation alone on vascular remodeling. We hypothesized that estrogens are atheroprotective, independent of their influence on lipid metabolism, by directly influencing the production and effects of a prototypical atherogenic mediator, basic fibroblast growth factor (bFGF). METHODS AND
RESULTS: Twenty-five female sheep were randomized to sham operation, ovariectomy, or ovariectomy plus 17beta-estradiol replacement. Serum cholesterol and triglyceride levels were serially measured for 1 year and were similar among groups and in the normal range (30 to 60 mg/dL). At 6, 9, and 12 months, ovariectomy resulted in aortoiliac intimal hyperplasia compared with sham (P<0.01) and hormone replacement (P<0.01) groups. The neointima of ovariectomized animals was characterized immunohistochemically by increased vascular smooth muscle cells (VSMCs). Levels of bFGF protein were determined in adjacent aortic segments. Ovariectomized sheep had 2-fold more FGF than sham or ovariectomized sheep that received hormone replacement. In vitro, estradiol inhibited the mitogenic effect of bFGF on human aortic VSMCs.
CONCLUSIONS: Without dietary manipulation, ovarian ablation alone induces aortic intimal hyperplasia in the ewe. Estradiol abrogates this response independently of its effects on serum lipids. Hormone replacement decreases the accumulation of the atherogenic peptide bFGF in vivo and inhibits the mitogenic response of VSMCs to bFGF in vitro. These results suggest that estrogens may provide atheroprotection both by modulating local production and by attenuating the influence of bFGF on VSMC growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808604     DOI: 10.1161/01.cir.98.19.2049

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity.

Authors:  Dharmendra Kumar Yadav; Feroz Khan; Arvind Singh Negi
Journal:  J Mol Model       Date:  2011-10-27       Impact factor: 1.810

Review 2.  Regulation of Transcription Factors by Reactive Oxygen Species and Nitric Oxide in Vascular Physiology and Pathology.

Authors:  Stefanie Kohlgrüber; Aditi Upadhye; Nadine Dyballa-Rukes; Coleen A McNamara; Joachim Altschmied
Journal:  Antioxid Redox Signal       Date:  2017-01-04       Impact factor: 8.401

Review 3.  Hormone replacement therapy in the prevention and treatment of atherosclerosis.

Authors:  L Mosca
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

4.  Development of QSAR model for immunomodulatory activity of natural coumarinolignoids.

Authors:  Dharmendra K Yadav; Abha Meena; Ankit Srivastava; D Chanda; Feroz Khan; S K Chattopadhyay
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

5.  The Activation Function-1 of Estrogen Receptor Alpha Prevents Arterial Neointima Development Through a Direct Effect on Smooth Muscle Cells.

Authors:  Natalia F Smirnova; Coralie Fontaine; Mélissa Buscato; Adrien Lupieri; Alexia Vinel; Marie-Cécile Valera; Maeva Guillaume; Nicole Malet; Jean-Michel Foidart; Isabelle Raymond-Letron; Francoise Lenfant; Pierre Gourdy; Benita S Katzenellenbogen; John A Katzenellenbogen; Muriel Laffargue; Jean-Francois Arnal
Journal:  Circ Res       Date:  2015-08-27       Impact factor: 17.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.